Gross Law Firm sets Oct. 5 deadline in Replimune shareholder notice

The Gross Law Firm said Replimune Group shareholders who bought shares during the stated class period may seek lead plaintiff appointment in a securities class action tied to FDA-related disclosures.

The Gross Law Firm issued a shareholder notice on Aug. 18, 2026, about a securities class action involving Replimune Group, Inc. It said the deadline to seek lead plaintiff appointment is Oct. 5, 2026.

The notice says the case covers investors who bought Replimune shares between Oct. 20, 2025, and Apr. 10, 2026. It also says lead plaintiff status is not required to take part in any recovery if the case moves forward.

According to the notice, the complaint alleges that defendants made materially false and/or misleading statements or omitted material facts. The allegations center on disclosures tied to the company’s biologics license application, or BLA, and concerns previously communicated by the Food and Drug Administration.

The notice says the company submitted data from an early unplanned analysis of RP1-104 that included 40 patients, described in the notice as 10% of the planned enrollment of 400 patients. It also says the allegations claim RPL-001-16 and RP1-104 had deficiencies that were likely to lead the FDA to reject the BLA.

The Gross Law Firm said the complaint also alleges that positive statements about Replimune’s business, operations and prospects were materially misleading or lacked a reasonable basis. The notice includes the firm’s New York contact information and says there is no cost or obligation to participate.

The notice does not itself determine wrongdoing. It is a shareholder solicitation tied to a pending securities class action, and the allegations remain unproven unless and until they are resolved in court.

Sources

• PR Newswire: The Gross Law Firm shareholder notice on Replimune Group, Inc.

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.